Riskpilot← Back to searchSign inGet full accessCutis Valens AB
ABActiveOrg 5591725071Lilla Danska Vägen 3General medical practice activities · NACE 8621Est. 20181 employees
Revenue 2025
SEK 1,2M
-18% vs 2024
EBITDA margin
-2.1%
-111% vs 2024
Equity ratio
54.0%
Financial strength
Net profit 2025
SEK 277K
+110% vs 2024
| Revenue | SEK 1,2M | -18% |
| EBITDA | SEK -25K | -111% |
| Net profit | SEK 277K | +110% |
| Total assets | SEK 677K | -34% |
| Equity | SEK 365K | -9% |
| Employees | 1 | — |
Legal name
Cutis Valens AB
Org number
5591725071
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
21 september 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva sjukvård, läkarverksamhet, estetiska behandlingar, sälja och marknadsföra hudprodukter, medicinska konsultationer samt därtill förenlig verksamhet i Sverige och utomlands.Konsultationstjänster och föreläsningar i samarbete med i första hand bolag verksamma inom hälso- och sjukvård, samt läkemedels och medicintekniskindustri. Deltaga i studier samt forskningsprojekt samt därmed förenlig verksamhet.
Address
Lilla Danska Vägen 3
Email
katri.granger@telia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 502 | 1 425 | 1 820 | 1 435 | 1 173 |
| Staff expenses | — | −913 | −989 | −865 | −862 |
| EBITDA | 545 | 337 | 562 | 238 | −25 |
| Depreciation & amort. | −5 | −5 | −10 | −12 | −6 |
| EBIT | 540 | 332 | 551 | 226 | −31 |
| Net financials | — | 0 | −7 | 4 | 47 |
| Profit before tax | 404 | 432 | 404 | 170 | 352 |
| Tax | −84 | −91 | −88 | −38 | −75 |
| Net profit | 320 | 341 | 317 | 132 | 277 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 958 | 921 | 1 285 | 1 024 | 677 |
| Equity | 477 | 548 | 582 | 401 | 365 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 80 | 72 | 262 | 121 | 146 |
| Total debt | 80 | 72 | 262 | 121 | 146 |
EBITDA margin
-2.1%
This company
15.8%
Market median
-113% vs market
20212025
Equity ratio
54.0%
This company
38.2%
Market median
+41% vs market
20212025
Return on equity
75.9%
This company
18.4%
Market median
+313% vs market
20212025
Net profit margin
23.6%
This company
8.1%
Market median
+191% vs market
20212025
Asset turnover
1.73×
This company
1.12×
Market median
+54% vs market
20212025
Debt / equity
0.85×
This company
0.62×
Market median
+37% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cutis Valens AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Katri Maria Granger | Board of Directors | 0 companies |
| Hans Magnus Granger | Deputy Board Member | 0 companies |